As of the latest Form 4 filed Feb 2, 2026.
What Arbutus Biopharma Corp insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 12 most recent filings for ABUS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-02-02 | 2026-02-02 | Nguyen Tuan Chief Financial Officer | AAward | +73.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-02 | 2026-02-02 | Androski Lindsay President and CEO | AAward | +28.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-02-19 | 2025-02-14 | Naftzger J. Christopher General Counsel and CCO | AAward | +54.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-02-19 | 2025-02-14 | McElhaugh Michael J. Interim President & CEO | AAward | +177K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-02-19 | 2025-02-14 | HASTINGS DAVID C Chief Financial Officer | AAward | +90.1K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-02-19 | 2025-02-14 | Sims Karen Chief Medical Officer | AAward | +49.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-02-05 | 2025-02-04 | HASTINGS DAVID C Chief Financial Officer | SSale | −22.2K | $3.28 | $72.8K | Yes (planned) | Form 4 ↗ |
| 2025-02-05 | 2025-02-04 | Sims Karen Chief Medical Officer | SSale | −19.3K | $3.28 | $63.5K | Yes (planned) | Form 4 ↗ |
| 2025-02-05 | 2025-02-04 | McElhaugh Michael J. Interim President & CEO | SSale | −23.8K | $3.28 | $78.1K | Yes (planned) | Form 4 ↗ |
| 2025-02-05 | 2025-02-04 | Naftzger J. Christopher General Counsel and CCO | SSale | −11.3K | $3.28 | $37.2K | Yes (planned) | Form 4 ↗ |
| 2024-08-16 | 2024-08-14 | MANCHESTER KEITH S Director | SSale | −8.85K | $3.69 | $32.6K | No | Form 4 ↗ |
| 2024-08-16 | 2024-08-14 | MANCHESTER KEITH S, Director | MExercise | +54.9K | $0.56 | $30.8K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ABUS’s full analysis or the market-wide insider trading feed. The tabs above jump to ABUS’s other SEC data.
Source: SEC Form 4 filings for ABUS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.